Page last updated: 2024-11-02

oxidopamine and Fatty Liver

oxidopamine has been researched along with Fatty Liver in 1 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Oben, JA1
Roskams, T1
Yang, S1
Lin, H1
Sinelli, N1
Li, Z1
Torbenson, M1
Huang, J1
Guarino, P1
Kafrouni, M1
Diehl, AM1

Other Studies

1 other study available for oxidopamine and Fatty Liver

ArticleYear
Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:3

    Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Body Weight; Diet; Fatty Liver; Hepatocytes; Li

2003